Operational Excellence:
The New Competitive Divide in Pharma

Despite scientific breakthroughs and sustained R&D investment, pharma’s financial performance has lagged behind other industries in recent years. From 2018 through late 2024, an equal-weight index of 50 leading pharma companies delivered a shareholder return of just 7.6%, compared to 15%+ for the S&P 500 over the same period (PwC). Even more telling: nearly 60% of the sector’s total value growth came from just two companies, leaving the rest of the industry struggling to keep pace.

So, what’s driving the gap?

First, pricing pressure is accelerating. Governments, payers and policymakers—particularly in the premium-priced U.S. market—are tightening their focus on affordability. Margins are being squeezed from all sides.

Second, volatility is now a constant. Geopolitical instability, conflict-related disruptions, and exposed supply chain dependencies have made global operations less predictable and far harder to manage. The industry’s long, complex supply chains were not designed for today’s level of uncertainty.

Finally, operational complexity is increasing faster than operational maturity. New types of therapies—like cell, gene, and mRNA-based treatments—require more specialized equipment, tighter controls and smaller, more variable batches. Combined with rapid shifts in market demand, this puts enormous stress on plants that still rely heavily on manual processes, fragmented communication and inconsistent standards.

The result? A widening performance divide. And at the center of that divide is operational excellence — or the lack of it.

Operational Excellence (OE) is often misunderstood as a cost-cutting program, but in pharmaceutical manufacturing, it’s something far more strategic. OE is a disciplined, data-driven approach to running operations in a consistent, reliable way while continuously raising performance standards. It aligns people, processes and technology so that every batch, every shift and every decision reflects the same high standard.

At its core, OE focuses on reducing variability and strengthening process discipline. That includes:

The widening performance gap in pharma isn’t just about science or strategy. It’s about execution. Companies with strong operational discipline are able to navigate pricing pressure, supply chain shocks and regulatory scrutiny with far greater stability than those relying on outdated, manual or inconsistent processes.

Operational Excellence gives pharma companies a real advantage by helping them:

• Respond faster to volatility: Standardized work and clear communication structures make it easier to adjust to fluctuating demand, material shortages or geopolitical interruptions.
• Reduce variation and defects: Less variability means fewer deviations, fewer delays, and higher confidence in every batch—a direct driver of both quality and competitiveness.
• Strengthen compliance and inspection readiness: Reliable documentation, consistent procedures and clear traceability reduce audit preparation time and lower the risk of findings.
• Improve agility without sacrificing quality: When processes are stable and well-defined, teams can adapt more quickly to new technologies, emerging therapeutic modalities and changing market requirements.

In short, companies that embed OE into their culture become more resilient, more predictable and more capable of delivering high-quality products under pressure. Those without it struggle with inconsistency, reactive firefighting and rising operational risk—a disadvantage that compounds over time.